Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL).
E. Jabbour
Honoraria - Bristol-Myers Squibb; Novartis
S. M. O'Brien
No relevant relationships to disclose
D. A. Thomas
No relevant relationships to disclose
F. Ravandi
No relevant relationships to disclose
S. York
No relevant relationships to disclose
M. Kwari
No relevant relationships to disclose
S. Faderl
No relevant relationships to disclose
T. M. Kadia
No relevant relationships to disclose
C. Wilson
Employment or Leadership Position - PPD Development
R. Tarnai
Employment or Leadership Position - PPD Development
A. S. Advani
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
G. Garcia-Manero
No relevant relationships to disclose
J. E. Cortes
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
H. Kantarjian
Research Funding - Pfizer